"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Clinical outcomes after 4F-PCC for warfarin-associated ICH and baseline GCS less than or equal to 8. Am J Emerg Med. 2022 09; 59:59-62.
-
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke. 2022 03; 53(3):728-738.
-
Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate. Ann Pharmacother. 2020 11; 54(11):1090-1095.
-
Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate. Thromb Haemost. 2020 Feb; 120(2):207-215.
-
Anticoagulation in Revision Total Joint Arthroplasty: A Retrospective Review of 1917 Cases. Orthopedics. 2019 Nov 01; 42(6):323-329.
-
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. JAMA. 2019 09 03; 322(9):834-842.
-
In-Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry. J Am Heart Assoc. 2019 04 16; 8(8):e011606.
-
Clotting-Factor Concentrations 5 Days After Discontinuation of Warfarin. Reg Anesth Pain Med. 2018 Aug; 43(6):616-620.
-
Detecting and managing device leads inadvertently placed in the left ventricle. Cleve Clin J Med. 2018 Jan; 85(1):69-75.
-
An unusual echo after ventricular tachycardia ablation. Heart. 2018 02; 104(4):359-360.